This user has not added any information to their profile yet.
I have many years of experience as a gynecologist, cancer biologist, translational cancer researcher and bioinformatician. Prior to coming to the U.S. for PhD studies, I had worked for several years as a gynecologist treating various gynecologic cancers. Subsequent to my PhD training, I have had more than a decade of experience in cancer biology and translational cancer research. My main research focus is understanding molecular mechanisms of tumor progression and drug resistance and developing genetic biomarkers for predicting clinical outcomes. More recently, I received a Master of Science in Informatics. This has given me the knowledge and skill to take advantage of the enormous amount of data from The Cancer Genomic Atlas Project and other "big data" for data mining. I have formed a startup company, Immortagen, with 3 other cofounders, in order to attract private funding to advance the development and validation of cancer predictive algorithms. Taking advantage of innovative tumor tissue processing and advanced algorithms, TEAPOT (Tumor Evolution Assay for Personalized Oncology Therapy) reconstructs tumor evolutionary history of individual patients based upon next generation sequencing data. TEAPOT has three major levels of utility: 1) it quantifies intra-tumor driver mutation prevalence to predict response to a targeted agent; 2) it locates multiple driver mutations in different portions of a tumor for design of an appropriate cocktail regimen; and 3) it determines the role of a mutation through estimating of its fitness in tumor evolution.
As President of Immortagen Inc., I am leading the effort to develop strategic partnership with industry leaders and beta test our various product lines in potential markets.
As Chief Scientific Officer, I am leading a team for the development of TEAPOT , a first-of-its-kind AI-based algorithm platform that empowers existing genetic tests by quantitatively identifying the crucial driver mutations in each tumor, potentially doubling the response rate. The quantitative enhancement in genetic testing reports will allow providers to predict clinical responses and select drugs with increased efficacy.